Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | POLB | P06746 | 3/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | BRAF | P15056 | 2/20 | 0.68 |
| ▸ | ATM | Q13315 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | APAF1 | O14727 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31358678 | 0.82 | KDM4E (0.70) | KDM4EALDH1A1POLBLMNABRAF | |
| SCHEMBL2554480 | 0.81 | POLB (1.00) | KDM4EALDH1A1POLBLMNAHPGD | |
| SCHEMBL8792096 | 0.80 | KDM4E (0.67) | KDM4EALDH1A1POLBLMNABRAF | |
| SCHEMBL14990949 | 0.80 | ALDH1A1 (0.67) | KDM4EALDH1A1POLBLMNABRAF | |
| SCHEMBL24445943 | 0.79 | KDM4E (0.65) | KDM4EALDH1A1LMNABRAFATM | |
| SCHEMBL20718445 | 0.78 | ALDH1A1 (0.63) | KDM4EALDH1A1POLBLMNAHPGD | |
| SCHEMBL18920576 | 0.78 | ALDH1A1 (0.63) | KDM4EALDH1A1POLBLMNABRAF | |
| SCHEMBL3068445 | 0.78 | KDM4E (0.63) | KDM4EALDH1A1POLBLMNABRAF | |
| SCHEMBL4336863 | 0.78 | KDM4E (0.83) | KDM4EALDH1A1POLBLMNABRAF | |
| SCHEMBL4336857 | 0.78 | KDM4E (0.83) | KDM4EALDH1A1POLBLMNABRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261980-A1 | Use of Thiazolidinone Derivatives as Antiangiogenic Agents | CELL THERAPEUTICS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20050042674-A9 | Common ligand mimics: thiazolidinediones and rhodanines | TRIAD THERAPEUTICS, INC. | 2005-02-24 | — | — | US | disclosed |
| US-20040009526-A1 | Common ligand mimics: thiazolidinediones and rhodanines | YU LIN (US) | 2004-01-15 | — | — | US | disclosed |
| WO-2003072033-A2 | COMMON LIGAND MIMICS: THIAZOLIDINEDIONES AND RHODANINES | TRIAD THERAPEUTICS, INC. (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009526-A1 | Common ligand mimics: thiazolidinediones and rhodanines | GPR65, NR2E3, FGFR3 | KDM4E 4288/4885ALDH1A1 1216/4885POLB 4843/4885 |
| US-20080261980-A1 | Use of Thiazolidinone Derivatives as Antiangiogenic Agents | EP300, HIF1A, HIF1AN | KDM4E 1039/4885ALDH1A1 65/4885POLB 1570/4885 |
| US-20050042674-A9 | Common ligand mimics: thiazolidinediones and rhodanines | GPR65, NR2E3, FGFR3 | KDM4E 4288/4885ALDH1A1 1216/4885POLB 4843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.